Be patient with yourself, consider working with a nutritionist to help you through your GLP-1 weight loss journey, and be sure to contact your doctor if your nausea, digestive discomfort, or other side effects feel severe.
The above findings indicate that AMPK activation enhances GLP-1 protection of INS-1 cells against cholesterol-induced toxicity
What the published data shows: According to a 2024 comparative review (Wei and Xu, 2024), which synthesizes findings from the SURMOUNT phase 3 tirzepatide trials (Jastreboff et al., NEJM 2022) and semaglutide data (Fras et al., NEJM 2021): Tirzepatide at the highest studied dose produced average excess weight loss that exceeded semaglutide comparators in reviewed cohorts Both drugs showed significant weight reduction versus placebo across trial populations Tirzepatide showed improvements in blood pressure, lipid profiles, and glycemic markers in obesity cohorts, beyond weight loss alone Important clinical caveat Trial results are population averages
Int J Cancer 91:236240 Bussolati B et al (2009) Anti-angiogenic properties of calcium trifluoroacetate
Those with severe or long-term issues often increase their dose later
